Floatz logo

syh2051

Gastric Cancer (GC)

Fujian Cancer HospitalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

282 Active assets in the Gastric Cancer (GC) cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
Epirubicin
Rondo Therapeutics
Phase 3BB

View all 50 →

Same molecule, other indications

syh2051 is also rated in:

breast cancerDormant
CC
Indicative ·
40 / 100
View asset →
cancerDormant
CC
Indicative ·
40 / 100
View asset →
head and neck cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →